NWBO (Northwest Biotherapeutics) LT-Debt-to-Total-Asset: 0.26 (As of Mar. 2026)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

Northwest Biotherapeutics Inc NWBO

What is Northwest Biotherapeutics LT-Debt-to-Total-Asset?

Northwest Biotherapeutics NWBO -3.95% 11 LT-Debt-to-Total-Asset is 0.26 as of Mar. 2026. GuruFocus rates NWBO with a GF Score™ of 11/100. The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Northwest Biotherapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.26.

Northwest Biotherapeutics's long-term debt to total assets ratio declined from Mar. 2025 (0.89) to Mar. 2026 (0.26). It may suggest that Northwest Biotherapeutics is progressively becoming less dependent on debt to grow their business.

Northwest Biotherapeutics (OTCPK:NWBO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Northwest Biotherapeutics LT-Debt-to-Total-Asset Related Terms

Northwest Biotherapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Northwest Biotherapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Northwest Biotherapeutics LT-Debt-to-Total-Asset Chart

Northwest Biotherapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.76

0.33

0.89

1.23

0.27

Northwest Biotherapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.89	0.93	1.18	0.27	0.26

11GF Score

Northwest Biotherapeutics Inc NWBO

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Northwest Biotherapeutics LT-Debt-to-Total-Asset Calculation

Northwest Biotherapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	22.289	/	81.29
	=	0.27

Northwest Biotherapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	20.502	/	80.051
	=	0.26

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.26 mean?

Northwest Biotherapeutics (NWBO) has a LT-Debt-to-Total-Asset of 0.26 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Northwest Biotherapeutics and its competitors.

Is Northwest Biotherapeutics' LT-Debt-to-Total-Asset too high?

Northwest Biotherapeutics' current LT-Debt-to-Total-Asset is 0.26. Overall, Northwest Biotherapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.

How does Northwest Biotherapeutics' LT-Debt-to-Total-Asset compare to LCTX and VRXA?

Northwest Biotherapeutics' LT-Debt-to-Total-Asset of 0.26 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Northwest Biotherapeutics and its competitors. Northwest Biotherapeutics's current LT-Debt-to-Total-Asset is 0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Northwest Biotherapeutics stock overvalued right now?

Northwest Biotherapeutics (NWBO) has a current LT-Debt-to-Total-Asset of 0.26. The current LT-Debt-to-Total-Asset is 0.26. Northwest Biotherapeutics' overall GF Score™ is 11/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Northwest Biotherapeutics (NWBO), the current LT-Debt-to-Total-Asset is 0.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Northwest Biotherapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies LCTX VRXA ABEO SLNCF GALT PALI IMRX IRD VSTM MGNX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges NBYB:Germany

Address 4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814

Website https://www.nwbio.com

Northwest Biotherapeutics Inc a biotechnology company focused on developing personalized immune therapies for cancer. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.

11GF Score

Get the complete analysis for NWBO

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.17

Price

View NWBO Analysis

See LT-Debt-to-Total-Asset data for all stocks →